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Can Your Privacy be Protected in an Internet Age?
By Suzanne Blaz
In addition to the recently discovered secret
wiretapping of American citizens' phones by the U.S.
Government,' recent advances in Internet and copy
protection technology are raising new security and
privacy concerns for consumers. Two instances of
particular import demonstrate that U.S. Internet and
computer privacy may be at risk in the future: Sony
BMG Music Entertainment's attempt to protect the
copyright of its music by installing a digital-rights-
management program onto compact discs, which
automatically install onto personal computers without
the owner's knowledge; 2 and Google's new desktop
software that is designed to help users move and search
their computer files, but allows access to this
information by Google3 and perhaps the U.S.
government, although the government's recent
subpoena for Google's Internet searches was denied.!
In the area of cyberlaw, privacy and copyright
issues are always of concern;' however, the law is not
always able to keep up with the technology and can
lead to Americans' private information and computers
being accessed by others without any recourse.6
Indeed, as Michael Hiltzik of the L.A. Times noted
regarding the government's wiretapping, "[i]t's plain
that the necessary ingredients for a surveillance program
on such a scale are the will and the technology. The
law no longer matters, because technology has left it
in the dust."'
Indeed, many users did not and still do not
know that Sony BMG was routinely installing a hidden
software program, known as the Extended Copy
Protection ("XCP"), on their CDs. This software is
essentially a rootkit,9 a relatively new term that
describes a file or folder that is invisible to the user, is
hidden from spy-ware or virus searches, degrades the
computer's performance and can control critical
computer functions, allowing others access to a
person's computer. Moreover, it has been deemed
"spyware" by Microsoft.' 0 This software was exposed
when Sony BMG released a utility program to help
users remove the rootkit component of the XCP from
their computers;" however, this program did not
effectively remove the rootkit software, but only
Recent threats to privacy have come from anti-piracy
software. internet search engines. and file transfer applica-
tions.
unmasked the hidden files created by the XCP, and
effectively disabled the consumers' computer CD
player from being able to play all CDs.12
Furthermore, the XCP anti-piracy software
not only masked its presence, but also introduced a
vulnerability that hackers and virus writers began to
target, which forced Sony to recall millions of its CDs.13
The XCP software gave not only Sony BMG, but also
hackers, a "back door" to access a user's computer,
because the rootkit that it installs, a security tool that
can capture computer passwords so that one can
access your computer remotely, collects information
from a user's personal computer and allows others
access to it without the user ever being aware of this
access.14
Sony BMG issued two public apologies and
recalled the CDs, stating, "[w]e deeply regret any
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inconvenience this may cause our customers."'" Steps
that Sony has taken to make reparations include a
proposed settlement that will pay consumers $7.50
per CD that had the XCP software or allow them three
free downloads of whole albums online.'" Additionally,
Sony has stated that it is committed to providing
software to help remove the rootkit;" however, the
program available on its web site to remove the
software is not entirely effective.'"
This incident has not only tarnished Sony's
image, but also brought government attention. On
February 16, 2006, after speaking with BMG execu-
tives, the director of law enforcement at the Depart-
ment of Homeland Security ("DHS"), Jonathan
Frenkel, issued a statement that the DHS may con-
sider outlawing rootkits, stating that, "[the government]
need [s] to be thinking about how we ensure that con-
sumers are not surprised by what their software pro-
grams do."' 9
In addition to threats from the DHS, Sony
BMG faces several lawsuits 20 as a result of the XCP
software, one of which was brought by the Electronic
Frontier Foundation ("EFF"), a non-profit group that
pledges to protect consumers' digital rights. 21 These
lawsuits allege, among other things, that Sony BMG
violated the federal Computer Fraud and Abuse Act2 2
and the federal Electronic Communications Privacy
Act23 in addition to common law invasion of property,
trespass to chattels and violation of State fraud acts.24
Despite the adverse publicity from the Sony
BMG incident, the entertainment industry continues
to experiment with rootkits and other programs to try
and protect their copyright. For instance, some copies
of the movie Mr & Mrs. Smith were released with
rootkit programs, 25 and Symantec also developed
rootkits to protect its copyright on the Norton Anti-
virus program it owns.26
There are laws that help companies who wish
to the protect their copyrighted material from being
dispersed to the masses over the internet, such as the
Digital Millennium Copyright Act ("DMCA") 27 passed
in 1998; however, this law is becoming more
controversial and may come under attack in situations
where the consumer is harmed. For instance, while
the DMCA makes it illegal for users to circumvent
digital protection software, it does not address situations
where it may be necessary for someone to bypass
harmful software, such as the rootkits on the Sony
CDS, or in order for consumers to make fair use of
the material they bought on different media that they
own. 2 8
Another security threat that looms over
Americans is Google's new desktop program, which
lets users automatically transfer information from one
personal computer to another and allow them to search
their desktop files; however, the user must allow Google
to store the material for up to 30 days. 29 This service
is available for free, but worries over this service have
arisen because of the U.S. government's recent
demands for searches made by users of Google's
search engine and other information.3 0
Google recently fought the U.S. Justice
Department over its subpoena for internet searches,
which the government wanted in order to compile data
in response to a Supreme Court case3' that cast doubt
on the constitutionality and effectiveness of the Child
Online Protection Act ("COPA").3 2 The Supreme
Court case is currently blocking COPA's usage in order
to protect free speech rights.3 3 The Justice Department
also asked for a random sample of one million Web
pages that can be searched through Google's site.34
Google argued that it would not comply with
the request because it gave the government unbridle
access to information about their users violating their
privacy, and also because compliance with the
subpoena would expose Google's trade secrets.35
Additionally, Google argued that the government failed
to demonstrate that the information would even be
admissible evidence in court.36 Other companies, such
as AOL and Yahoo, chose not to fight the government
and complied with the request for their Web pages
and user's search information already.37
On March 17,2006, U.S. District Court Judge
James Ware ruled that Google was not required to
provide the internet searches, but was required to work
with the government to construct a way to randomily
obtain 50,000 Web Pages that could be handed over.38
The Court ultimately granted part of the Justice
Department's request because it was narrowly tailored,
but gave Google time to file objections to this order if
(Tech Privacy, continued on page 28)
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Bioshield 2: A Shot in the Right Direction?
By Lindsay Frank
Despite the introduction of the Biodefense and
Pandemic Vaccine & Drug Development Act of 2005
("Bioshield 2"),' pharmaceutical companies are still
reluctant to enter into the business of mass-producing
vaccines,2 and critics of the bill condemn the blanket
liability protections it provides to these companies.3
Introduced by Sen. Richard Burr (R-N.C.)
on October 17, 2005, Bioshield 2 was approved by a
voice-vote the next day by the Senate Health,
Education, Labor and Pensions Committee.' Bioshield
2 will allow drug companies to bypass typical testing
procedures for new vaccines and drugs in case of an
avian pandemic flu outbreak or bioterrorist attack.5
Moreover, Bioshield 2 aims to shield the
pharmaceutical companies who develop the vaccines
against personal injury lawsuits brought by individuals
suffering from adverse reactions or side effects caused
by the vaccine.6 The bill would offer 10-year market
exclusivity to drug companies, which would prevent
competitors from developing more affordable generic
alternatives.
This bill replaces the original Bioshield II
legislation that was designed by Sens. Joseph
Lieberman (D-Conn.) and Orrin Hatch (R-Utah).8
Bioshield II died because its "wild card" patent( 2x
kI I; V[1 I
Planning a national defense against bioterrorism and
pandemic disease has proved contentious among politicians,
pharmeccutical corporations, and public interest groups.
provision would have allowed pharmaceutical
companies developing bioterrorist countermeasures to
extend patents on their popular and exceedingly more
profitable drugs, even if those drugs were unrelated to
the production of countermeasures.9
For several years, the Bush Administration has
desired that pharmaceutical companies increase their
production of biodefense countermeasures with little
or no incentives.'o In fact, shortly after the anthrax
attacks in 2001, the Center for Disease Control
("CDC") asked Bayer Pharmaceutical, the makers of
Cipro, to get the FDA to approve the drug as a
treatment for anthrax." Bayer acted in accordance
with this request at their expense and further donated
four million doses of Cipro to the government.12
However, Bayer refused to comply with the
government's subsequent demand of an additional one
million doses at a discounted price, despite threats to
suspend their patent on Cipro.'I Recognizing the need
to provide pharmaceutical companies with greater
incentives, Project Bioshield was signed into law in
2004.14 The law provided the government with $5.6
billion over the next 10 years for the purchase of
vaccines and countermeasures designed to protect
Americans against anthrax, small pox and a chemical,
biological, radiological or nuclear ("CBRN") attack.
Despite the incentives to lure certain drug
makers into the biodefense and pandemic flu market,
very few of the large pharmaceutical companies jumped
at the opportunity to accept the grants offered by the
government.1 6 One reason for their skepticism was
the probable cost of approximately $800 million to $1
billion to develop a new drug without a guaranteed
market for it.'1 Additionally, the large pharmaceutical
companies did not avail themselves of the grant
because they were reluctant to divert research from
their popular and highly lucrative drugs to those that
are stockpiled and used in the event of an unlikely
emergency.'" The pharmaceutical industry was also
concerned with potential liability for administering
bioterror drugs that cannot first be tested on humans. 9
(Bioshield 2, continued on page 20)
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In response to the lack of eagerness from larger
pharmaceutical companies, some of the smaller
pharmaceuticals companies have stepped up to the
challenge in order to obtain a government contract. 20
Yet, in some instances, their tremendous efforts and
equally high expectations have been met with
disappointing results. 2 1 For instance, Hollis-Eden
Pharmaceuticals, a small company located in San
Diego, experienced first hand what many other
companies had feared most.2 2 The company eagerly
pursued what would be its first government contract
and spent more than $100 million to develop Neumune,
a medicine designed to combat acute-radiation
sickness.23 Yet after the Department of Health and
Human Service's ("DHHS") initial request for bids,
Hollis-Eden learned that the government only planned
to buy 20,000 to 200,000 doses of their drug.24 This
number severely conflicted with what many industry
watchers believed would be a proposal for doses
numbering in the millions.2 5 While the DHHS
eventually stated that this was only a preliminary
number,26 it is not surprising that many companies have
shied away from the potentially devastating risks in
order to set their sights on more predictable and
profitable endeavors.2 7
Yet after increased fears of another biological
threat, avian flu, began to surface, the Bush
Administration pushed for measures to fix some of
Project Bioshield's highly criticized provisions? Due
to exceedingly high expenses and potential liability, the
major pharmaceutical players pressed the legislature
for more incentives to encourage entry into the
speculative market of bioterrorist and pandemic flu
countermeasures.29
Accordingly, Bioshield 2 was developed and
proposes to create a new federal agency called the
Biomedical Advanced Research and Development
Agency ("BARDA") that would promote and
coordinate "advanced research and development of
drugs and vaccines in response to bioterrorism and
natural disease outbreaks."3 0 Moreover, BARDA
would further streamline the approval process for
biodefense products and assist companies from the
early stages of product development until they are
ready to bid on a government contract.3 1 Currently,
FEATURES
the Department of Homeland Security is responsible
for developing bioterrorism countermeasures. Under
Bioshield 2, BARDA would be protected from the
Federal Advisory Committee Act and the Freedom of
Information Act, which has sparked much controversy
over the bill.3 3 The Federal Advisory Committee Act
ensures that advice given to the executive branch" is
also given to the public, while the Freedom of
Information Act requires federal agencies to make their
records available to the public to the extent that they
are available.35 Instead, BARDA would be supervised
by a political appointee and proposes to allow the
research and development behind vaccines to be kept
secret from the public.36 Additionally, evidence of
deaths and injuries occurring from drugs and vaccines
labeled as "countermeasures" would also be kept
under wraps.37
"It's appalling that in the guise of a
health-related bill, the government is
giving the vaccine industry
unprecedented inununity for the harm
that their product can cause."
-Amber Hard, staff director for the Center for
Justice and Democracy
Bioshield 2 comes in wake of a $7.1 billion
strategy outlined in November 2005 by the Bush
Administration to expand and accelerate
pharmaceutical companies' capacity to produce
vaccines within the United States, stockpile treatments
against the H5N 1 avian influenza A virus, and detect
and respond to a pandemic flu outbreak.38 In addition,
Congress passed a defense bill last December that
included $3.8 billion, "mainly for flu vaccines and
medicines."39 The Bush Administration is hopeful that
the new legislation will appease the pharmaceutical
industry and enable companies to produce enough
vaccines for every American within six months of the
start of a pandemic outbreak."
Proponents of the bill argue that a liability
waiver is essential to avoid frivolous lawsuits, which
they attribute to hindering the progress of vaccine
(Bioshield 2, continued on page 21)
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developments in recent decades. 41 They also assert
that a victim suffering from harmful side effects stemming
from a pandemic vaccine will not be left without a viable
remedy as the legislation plans to provide for a
compensation fund modeled after the Smallpox
Compensation Fund.4 2 The fund would allow injured
victims and their families to apply for death benefits,
lost income and medical expenses.4 3 In addition, the
DHHS has the right to waive the liability shield if a
pharmaceutical company is found to have willfully
neglected the risks associated with their product."
Critics of the legislation, including health, consumer
and union groups, 45 believe that pharmaceutical
companies' expressed fear of lawsuits is misplaced
and merely a way to avoid compensating injured
victims.4 6 In fact, only 10 lawsuits have been filed
against makers of influenza vaccines in the past 20
years.4 7 Additionally, despite the seeming lack of
enthusiasm from many pharmaceutical companies
towards Bioshield,4 8 the threat of lawsuits has not
inhibited some major manufactures of vaccines against
influenza such as Merck, Roche, Wyeth, Novartis and
GlaxoSmithKline from investing millions to increase
their stockpile.49 In particular, vaccine manufacturer
Santa Fe Pasteur has spent $150 million to double its
production capacity.50
Many Democrats opposed to the legislation
argue that Bioshield 2's liability protections are
detrimental to the public's best interest without a
sufficient compensation fund for those injured by the
vaccine.5 ' Although Republicans believe that a
compensation plan should be set up for "first
responders," many assert that it is nearly impossible
to set up a fund for those who take the drugs after a
bioterrorist attack, as compensation needs would be
contingent on the circumstances of each situation.52
This rather laissez faire approach to a compensation
policy is what worries critics who have compared the
lack of a tangible fund to the ultimate failure of the
Smallpox Vaccine and Compensation Act of 2003.53
The Act was designed to pursue the ultimate goal of
vaccinating approximately 500,000 public healthcare
workers against smallpox, but was unsuccessful largely
because of the government's failure to execute a
legitimate compensation plan.54 As a result, only
40,000 healthcare workers actually took part in the
vaccination program." Similarly, without a legitimate
compensation fund, critics of Bioshield 2 assert that
Americans will be largely hesitant to take these drugs
in the event of a biological attack or pandemic
outbreak.56
According to Amber Hard, staff director for
the Center for Justice and Democracy in Illinois, "[i]t's
appalling that in the guise of a health-related bill, the
government is giving the vaccine industry
unprecedented immunity for the harm that their product
can cause." 17 Hard went on to say that Bioshield 2
"makes all of us living guinea pigs and gives
pharmaceutical companies carte blanche to develop
drugs [that may not be safe for the general public].""
This is not the first time the government has
shielded pharmaceutical companies from liability against
lawsuits. Over the past 30 years, the government has
issued major liability protection and compensation
programs such as the National Swine Flu Immunization
Program of 1976,59 the National Childhood Vaccine
Injury Compensation Act of 198660 and the Phase I
Smallpox Vaccination Program that was launched in
2003.61 Yet the National Swine Flu Immunization
Program of 1976 did not limit the amount of
compensation recoverable by victims. 6 2 Rather, this
Act required injured victims to file their claims against
the government after filing an administrative claim. 63
The government was then able to "seek indemnification
from negligent parties covered by the liability
protections."" The National Childhood Vaccine Injury
Compensation Act of 1986 allowed injured plaintiffs
to go to court if they were not satisfied with the
administrative result and merely disallowed punitive
damages so long as the company had complied with
the Federal, Food, Drug and Cosmetic Act and the
Public Health ServiceAct.65 Finally, the more stringent
restrictions imposed by the smallpox vaccination
program proved catastrophic to the legislation as
people refused to subject themselves to the vaccine
without the possibility of adequate compensation.66
Similar to those opposed to the Smallpox
Vaccination Program, critics of Bioshield 2 argue that
the bill places too much emphasis on protecting
(Bioshield 2, continued on page 30)
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Sharp Increase in Heating Prices and Limited Gov-
ernment Assistance Spark Concerns about Potential
Home Heating Crisis
By Claire Mariano
While volatile energy prices have prompted the federal
government to increase its funding of the Low-Income Home
Energy Assistance Program, spending is still $2 billion below
the program's dicretionary limit and does not serve over 25
million poor households.
High energy prices and continued debate over
funding for the Low-Income Home Energy Assistance
Program ("LIHEAP")' has led to an outcry from
advocacy organizations, some elected officials and
others concerned with affordability of winter heating
bills for low-income families. The U.S. Department of
Energy's Energy Information Administration ("EIA")
estimates that households heating with natural gas will
spend, on average, $257 more in fuel costs this winter,
about a 35 percent increase from last winter.2 For
households using heating oil, the EIA estimates that
these households will average about $275, or 23
percent, more in heating costs when compared to last
winter.
Behind these market shifts, the EIA cites weak
natural gas production, decreased natural gas imports,
high natural gas demand and high oil prices.' In
addition, Aviva Aron-Dine, representative of the Center
for Budget and Policy Priorities, noted that "heating
costs have increased for a variety of reasons this year,
but the disruptions caused by Hurricanes Katrina and
Rita certainly have played a significant role."I
An Increased Energy Burden on Low-Income
Households
Advocates for low-income families and public
policy organizations argue for greater LIHEAP funding
by analyzing the heavy energy burden on low-income
households. 6 LIHEAP provides basic bill payment
assistance for heating and cooling costs, as well as
some funding for weatherization programs.' Despite
the dramatically increased energy costs, LIHEAP
funding is appropriated at essentially the same level
this year, and current projections mean that the low-
income households will likely pay the difference.'
According to Economic Opportunity Studies,
families in poverty will spend about 25 percent of their
Fiscal Year 2006 income on energy bills.9 There are
about 13 million such households in poverty, and there
are about 33 million people considered LIHEAP-
eligible. 0 For the LIHEAP eligible population, energy
bills will consume about 16 percent of their annual
income."' The burden on low-income households can
be contrasted with median-income households, whose
average income was just over $47,000 in 2005.12
Median-income households will need to spend more
than 5 percent of their annual income, after adjusting
income for inflation. 13
"Instability with the cost of energy (especially
natural gas) is most worrisome for low-income
families, whose tight budgets allow little flexibility in
spending," said John Colgan, Director of Public Policy
for the Illinois Community Action Association. "Winter
heating costs can easily push low-income households
into a cycle of increasing debt and/or service
disconnections."l4
(Energy Assistance, continued on page 23)
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